To investigate predictors of response, remission, low disease activity, damage, and drug discontinuation in patients with systemic lupus erythematosus (SLE) who were treated with belimumab.
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting
Orsolini, Giovanni;Rossini, Maurizio;
2020-01-01
Abstract
To investigate predictors of response, remission, low disease activity, damage, and drug discontinuation in patients with systemic lupus erythematosus (SLE) who were treated with belimumab.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Early Disease and Low Baseline Damage as Predictors Gatto et al AR 2020.pdf
non disponibili
Tipologia:
Documento in Post-print
Licenza:
Accesso ristretto
Dimensione
422.23 kB
Formato
Adobe PDF
|
422.23 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
